Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q2 2024 (June 30)10holders +2
3new positions
1sold out
$5.61avg. 13F price*
At the end of Q2 2024, 10 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, up 2 from Q1 2024. 3 opened new positions and 1 sold out. The largest holders were Palo Alto Investors LP ($44.5M), Nomura Holdings Inc. ($16.4M) and BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($5.4M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2024 → Q2 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $47.2M |
| Exits | 1 | $33.4M |
All 13F filers, Q1 2024 → Q2 2024: 2,703,123 shares bought and 37,312,000 shares sold, net −34,608,877 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 10 holders
| Palo Alto Investors LP | 5.16% | New | 183,123 | $44.5M |
| Nomura Holdings Inc. | 0.11% | No change | 67,606 | $16.4M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 4,950,000 | $5.4M |
| New York State Common Retirement Fund | 0.01% | Reduce -29.6% | 3,706,000 | $4.0M |
| Ghisallo Capital Management LLC | 0.24% | New | 2,500,000 | $2.7M |
| Liberty Mutual Group Asset Management Inc. | 0.20% | Reduce -16.7% | 1,270,000 | $1.4M |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $647K |
| Sei Investments Co. | 0.00% | No change | 99,000 | $107K |
| Choreo, LLC | 0.00% | New | 20,000 | $22K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 3,000 | $3K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.